Summary - ASND - NASDAQ - Weiss Ratings

D

Ascendis Pharma A/S ASND

$161.52 $7.094.59% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$111.09 - $183.00

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (Navepegritide)

5/13/2025 - Globe Newswire

12 Best Growth Stocks to Buy and Hold for the Long Term

5/13/2025 - Insider Monkey

Janus Henderson Group PLC Purchases 193,688 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

5/13/2025 - MarketBeat

New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

5/12/2025 - Globe Newswire

Cantor Fitzgerald Has Weak Outlook for ASND FY2025 Earnings

5/10/2025 - MarketBeat

Driehaus Capital Management LLC Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

5/10/2025 - Ticker Report

Ascendis Pharma A/S (ASND, $151.25) price may climb as it broke lower Bollinger Band on May 09, 2025

5/10/2025 - Tickeron - Technical Analysis

Ascendis Pharma A/S (ASND, $151.25) price exceeded its 50-day Moving Average on May 09, 2025

5/10/2025 - Tickeron - Technical Analysis

Fred Alger Management LLC Sells 146,356 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

5/9/2025 - Ticker Report

Ascendis Pharma A/S (ASND, $159.39) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 8, 2025

5/9/2025 - Tickeron - Stocks

Ascendis Pharma A/S (ASND, $159.39) Stochastic Oscillator left the oversold zone on May 08, 2025

5/9/2025 - Tickeron - Stocks

Morgan Stanley Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to "Overweight"

5/7/2025 - MarketBeat

Bellevue Group AG Takes $344,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)

5/7/2025 - MarketBeat

Stifel Financial Corp Has $2.35 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

5/7/2025 - MarketBeat

Wedbush Equities Analysts Raise Earnings Estimates for ASND

5/7/2025 - MarketBeat

Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

5/6/2025 - Simply Wall St

Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1

5/6/2025 - Yahoo! Finance: News

Ascendis Pharma A/S (ASND, $170.74) Stochastic Oscillator left the overbought zone on May 05, 2025

5/6/2025 - Tickeron - Technical Analysis

Ascendis Pharma A/S (NASDAQ:ASND) Releases Earnings Results, Misses Expectations By $0.10 EPS

5/5/2025 - MarketBeat

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

5/5/2025 - Globe Newswire

Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Evercore ISI Analyst Says

5/4/2025 - MarketBeat

Aquatic Capital Management LLC Takes $230,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)

5/4/2025 - Ticker Report

RA Capital Management L.P. Buys 402,316 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

5/3/2025 - MarketBeat

Ascendis Pharma's Earnings Call: Growth Amid Challenges

5/3/2025 - TipRanks Financial Blog

Ascendis Pharma A/S (ASND, $167.47) RSI Indicator left the overbought zone on May 01, 2025

5/2/2025 - Tickeron - Technical Analysis

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Thursday, May 1, 2025

Period Date

Monday, March 31, 2025

Next Filing

Week of Sep 1 and 5 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Sep 12, 2024 - $111.09

52-week High

May 02, 2025 - $183.00

Valuation

Market Cap

$9.32B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

ascendispharma.com

Phone Number

45 70 22 22 44

Address

Tuborg Boulevard 12
Hellerup, 2900

Country

Year Founded

Business Description

Sector

--

Industry

--

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and... more